Research & Patient Center
Clinical Trials and Studies
The Lois Insolia ALS Clinic at the Les Turner ALS Research and Patient Center at Northwestern University Medicine is actively involved in multi-center drug trials. Robert Sufit, MD, Senda Ajroud-Driss, MD and Pat Casey, MS, OTR/L, CCRC, oversee the various ALS therapeutic clinical drug trials.
For a listing of current drug trials being conducted at the clinic, please visit the clinical trials section of the Centers for Disease Control website. General questions about eligibility for specific drug trials can be directed to ALSresearch@nm.org.
Information on ALS clinical trials being done at other locations nationwide can be found at the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) website.
Center Chosen as Only Site in Illinois for Phase 3 Clinical Drug Trial
The Foundation is pleased to announce the start of a new clinical drug trial for ALS at the Lois Insolia ALS Clinic at the Center. VITALITY-ALS is a Phase 3 clinical trial designed to evaluate the safety and effectiveness of tirasemtiv, an investigatory drug candidate under evaluation for the potential treatment of ALS. The objective of the clinical trial is to assess the effect of tirasemtiv versus placebo on respiratory function.
The study is sponsored by Cytokinetics, a biopharmaceutical company in San Francisco, California.
People with ALS in Illinois who wish to be considered for this trial should email the Lois Insolia ALS Clinic.
More information about VITALITY-ALS can be found here.